The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms
Open accessAbstract
Abnormal Rac1 signaling is linked to a number of debilitating human diseases, including cancer, cardiovascular diseases and neurodegenerative disorders. As such, Rac1 represents an attractive therapeutic target, yet the search for effective Rac1 inhibitors is still underway. Given the adverse effects associated with Rac1 signaling perturbation, cells have evolved several mechanisms to ensure the tight regulation of Rac1 signaling. Thus, characterizing these mechanisms can provide invaluable information regarding major cellular events that lead to aberrant Rac1 signaling. Importantly, this information can be utilized to further facilitate the development of effective pharmacological modulators that can restore normal Rac1 signaling. In this review, we focus on the pathological role of Rac1 signaling, highlighting the benefits and potential drawbacks of targeting Rac1 in a clinical setting. Additionally, we provide an overview of available compounds that target key Rac1 regulatory mechanisms and discuss future therapeutic avenues arising from our understanding of these mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 1×
“further supporting a role for this this mutation in melanoma progression.(81) Whole exome sequencing data from 74 tumor and normal sample pairs also identified”
BackgroundExome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 1×
“ing cascades driven by the Rac GEF Vav or the activation of the closely related small GTPases, RhoA and cell division control protein 42 homolog (Cdc42).(152) Interestingly, NSC23766-mediated Rac1 inhibition has been shown to inhibit Rac1-driven pro-tumorigenic effects in a number of cancer models.”
BackgroundTiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H. A., Wirtz, S., Becker, C., Atreya, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16432 · Cited by 828
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683 · cited 1×
“It has long been established that Rac1 drives tumor initiation, via serving as a Ras downstream effector, with in vitro data demonstrating the requirement of Rac1 for full oncogenic Ras transformation of NIH3T3 cells.(47) In vivo studies have also highlighted the importance of Rac1 in”
BackgroundDifferential Localization of Rho Gtpases in Live Cells
Michaelson, D., Silletti, J., Murphy, G., D'Eustachio, P., Rush, M., & Philips, M. R. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.111 · Cited by 679
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 1×
“Interestingly, one GGTI, GGTI2418, has entered clinical trials.(176) It would be interesting to examine, whether in a clinical setting this inhib-”
BackgroundDe Wever, O., Nguyen, Q., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., & Mareel, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1110fje · Cited by 402
Cited by
The clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876
Scheiblich, H., Eikens, F., Wischhof, L., Opitz, S., Jüngling, K., Cserép, C., Schmidt, S. V., Lambertz, J., Bellande, T., Pósfai, B., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.06.029 · Cited by 207
Fu, H., Alabdullah, M., Großmann, J., Spieler, F., Abdosh, R., Lutz, V., Kalies, K., Knöpp, K., Rieckmann, M., Koch, S., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2109-9 · Cited by 51
Tomino, T., Tajiri, H., Tatsuguchi, T., Shirai, T., Oisaki, K., Matsunaga, S., Sanematsu, F., Sakata, D., Yoshizumi, T., Maehara, Y., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.073 · Cited by 24
Chan, W. W. R., Li, W., Chang, R. C. C., & Lau, K. (2020) · The FASEB Journal · doi:10.1096/fj.202001703r · Cited by 20
Metadata
- Authors
- Marei, H., & Malliri, A.
- Venue
- Small GTPases
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 8
- Issue
- 3
- Pages
- 139-163
- ISSN
- 2154-1248 (ISSN-L)
- 2154-1256
- OpenAlex
- W2493059034
- Cited by
- 168
- References
- 18
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms. https://app.cochat.ai/papers/10.1080/21541248.2016.1211398
- The paper
- Marei, H., & Malliri, A. (2017). Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases. https://doi.org/10.1080/21541248.2016.1211398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.